Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 10/20 | 0.57 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.52 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.51 |
| ▸ | HTR1A | P08908 | 2/20 | 0.49 |
| ▸ | HTR7 | P34969 | 2/20 | 0.49 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TNKS | O95271 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6796643 | 0.83 | PARP1 (0.53) | PARP1PDE10APARP2 | |
| SCHEMBL17180434 | 0.81 | LMNA (0.59) | PARP1PDE10APARP2TNKS2KMT2A | |
| SCHEMBL6795998 | 0.77 | PARP1 (0.58) | PARP1PDE10APARP2HTR1AHTR7 | |
| SCHEMBL6795593 | 0.76 | PARP1 (0.64) | PARP1PDE10APARP2TNKS2KMT2A | |
| SCHEMBL16404338 | 0.76 | PDE10A (0.84) | PARP1PDE10APARP2TNKS2KMT2A | |
| SCHEMBL6795464 | 0.75 | PARP1 (0.63) | PARP1SIGMAR1PDE10APARP2HTR1A | |
| SCHEMBL6795780 | 0.74 | PARP1 (0.61) | PARP1SIGMAR1PDE10APARP2HTR1A | |
| SCHEMBL23073611 | 0.74 | PARP1 (0.73) | PARP1PDE10APARP2HTR1AHTR7 | |
| SCHEMBL168776 | 0.74 | PARP1 (1.00) | PARP1PDE10APARP2HTR1AHTR7 | |
| SCHEMBL6791216 | 0.74 | PARP1 (0.73) | PARP1PDE10APARP2HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077667-A1 | Quinazolinone derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1355888-A1 | QUINAZOLINONE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002048117-A1 | QUINAZOLINONE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077667-A1 | Quinazolinone derivatives | PARP1, PARP9, PARP2 | PARP1 1/4885GRIN2B 2644/4885SIGMAR1 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.